Healthcare Industry News: Relenza
News Release - January 24, 2006
BioAlliance Pharma Appoints Former GlaxoSmithKline Executive as Vice President of Sales & MarketingSpecialty Pharma Company Strengthens Management Team in Advance of Commercial Launch Of Loramyc(R)
PARIS--(HSMN NewsFeed)--Jan. 24, 2006--BioAlliance Pharma (EURONEXT:BIO)(BOURSE:BIO), an emerging specialty pharmaceutical company focused on the development of innovative therapeutics targeting drug resistance in cancer, HIV, and severe and opportunistic infections, announced today the appointment of Florence Dupre to the newly created position of Vice President of Sales and Marketing. In this position, Ms. Dupre will be responsible for building and leading the company's commercial capabilities.
"Florence has a strong background in hospital-focused commercial operations both in France and in the European Union, and we are delighted to have her join our organization as we prepare for the European launch of our lead product, Loramyc®, for treatment of oropharyngeal candidiasis," commented Dominique Costantini, MD, BioAlliance president and CEO. "We look forward to working with Florence to build the foundation for our sales organization in France, followed by what we plan to be a future expansion of this sales force into other EU countries."
Ms. Dupre, age 35, is an experienced pharmaceutical industry executive who has held positions of increasing responsibility at GlaxoSmithKline (GSK), most recently as Director of Hospital Commercial Activities, France. In this post, she was responsible for developing the commercial strategy for all of GSK France's hospital products as well as for negotiations with the hospitals. Prior to this position, she was Marketing Strategy Director - HIV, Europe, responsible for GSK HIV programs, and in particular for the launch of Telzir® (antiprotease) throughout the EU. Earlier, she was Product Manager, France, and launched Relenza®, an innovative antiviral for treatment of type A and B influenza. Previously, she held product marketing positions at Bristol-Myers-Squibb in virology, where she was in charge of two nucleoside reverse transcriptase inhibitors (NRTIs) Zerit® and Videx® for treatment of HIV, and at Bayer Pharma, where she was involved with the launch of Glucor® for treatment of diabetes.
Ms Dupre holds a research degree (DEA) in Immunology and Toxicology from the Pasteur Institute and Necker Hospital and a Masters Degree in Biology and Biochemistry from the Ecole Normale Superieure - Ulm. She also holds a Masters Degree in Marketing and Management from ESSEC, the French business school.
About BioAlliance Pharma
BioAlliance Pharma SA (EURONEXT:BIO)(BOURSE:BIO) is an emerging specialty pharmaceutical company focused on the development of innovative therapeutics targeting drug resistance in cancer, HIV, and severe and opportunistic infections. The Company is developing three broad product ranges based on the Lauriad® adhesive technology which allows an early and prolonged release of therapeutic agents at the site of the disease, the Transdrug® nanoparticle technology designed specifically for intracellular targeting, and a New Chemical Entities programme focused on development of new drugs in oncology and HIV.
The Company's most advanced product, the Loramyc® (miconazole Lauriad®) 50 mg Bioadhesive Buccal Tablet, has completed two Phase III clinical trials in Europe for treatment of oropharyngeal candidiasis (OPC) in cancer and HIV patients. In September 2005, BioAlliance filed a request for Marketing Authorisation (MAA) in Europe for this product. Under an IND allowed by the US Food and Drug Administration (FDA), a pivotal Phase III trial of Loramyc® is expected to initiate in the US in 2006 for the same indication. A second product, acyclovir Lauriad®, for the treatment of oral herpes, has completed a Phase I clinical trial in Europe. A Phase I/II trial in primary liver cancer (hepatocellular carcinoma or HCC) utilizing the Company's doxorubicin Transdrug® nanoparticle delivery technology is ongoing in Europe, and has been granted orphan drug status by the EMEA and the FDA.
This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements please refer to the Risk Factors (Facteurs de Risque) section of the prospectus approved by the AMF (visa number 05-803) (section 3 of the Company's Document de base filed with the AMF under the number I.05-132 on 15 November 2005 and section 2 of the Note d'operation dated 22 November 2005), as available on the AMF website http://www.amf-france.org or BioAlliance Pharma S.A.'s website http://www.bioalliancepharma.com.
Source: BioAlliance Pharma
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.